For diffuse, unresectable intrahepatic cholangiocarcinoma in a young patient found to have a somatic and germline BRCA2 mutation whose tumor also harbors a BRAF V600E mutation, how would you sequence therapy after cisplatin, gemcitabine, and pembrolizumab?